Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hengli botulinum toxin A for primary axillary hyperhidrosis (phase III, double-blind, placebo-controlled)
ChiCTR2500104529Phase 3Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential axillary hyperhidrosis and axillary bromhidrosis comparing Hengli botulinum toxin A with Placebo (2 arms). Primary endpoint: Proportion of subjects with ≥50% reduction in axillary sweat weight from baseline. Started Jun 2025; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
essential axillary hyperhidrosisaxillary bromhidrosis
Beyond the preview
Go deeper on ChiCTR2500104529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104529.